Principles of antibiotic therapy in ocular surface diseases

Article Sidebar

PDF (Język Polski)


Published: Mar 31, 2014
Keywords:
conjunctivitis, antibiotics, antibiotics resistnce

Main Article Content

Marek E. Prost
Klinika Okulistyki, Wojskowy Instytut Medycyny Lotniczej w Warszawie

Abstract

Ocular surface diseases are one of the most frequent causes of consultation in ophthalmologist practices. Usually there are patients with conjunctivitis. Therefore the aim of this paper is to present up to date possibilities of treatment of this diseases with drawing special attention on the emerging antibiotic resistance. Practical guidelines on the use of antibiotics in the treatment of ocular surface disease are also discussed. The newer, 4 generation fluoroquinolones should be used as the first choice treatment of conjunctivitis because of the best efficacy, the highest penetration to the conjunctiva and the smallest possibility of the development of antimicrobial resistance.

Downloads

Download data is not yet available.

Article Details

How to Cite
1.
Prost ME. Principles of antibiotic therapy in ocular surface diseases. Ophthatherapy [Internet]. 2014Mar.31 [cited 2024Nov.22];1(1):26-2. Available from: https://journalsmededu.pl/index.php/ophthatherapy/article/view/668
Issue
Vol 1 No 1 (2014)
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Alabaiad CR, Miller D, Schiffman JC et al. Antimicrobial resistance profiles of ocular and nasal flora in patients undergoing intravitreal injections. Am J Ophthalmol. 2011; 152: 999-1004.
2. Blondeau JM. Fluoroquinolones: Mechanism of action, classification, and development of resistance. Surv Ophthalmol. 2004; 49(supl. 2): S73-8.
3. Filipek B, Prost M. Leki stosowane w leczeniu chorób infekcyjnych oczu. W: Kliniczna farmakologia okulistyczna. In: Prost M, Jachowicz R, Nowak JZ (ed). Elsevier, Wrocław 2013.
4. Fintelmann RE, Hoskins EN, Lietman TM et al. Topical fluoroquinolone use as a risk factor for in vitro fluoroquinolone resistance in ocular cultures. Arch Ophthalmol. 2011; 129: 399-402.
5. Gominet M, Seghezzi N, Mazodier P. Acyl depsipeptide (ADEP) resistance in Streptomyces. Microbiology. 2011; 157: 2226-34.
6. Hauser AR. Antibiotic basics for clinicians: The ABCs of choosing the right antibacterial agent. Lippincott Williams & Wilkins, 2012.
7. Hwang DG. Fluoroquinolone resistance in ophthalmology and the potential role for newer ophthalmic fluoroquinolones. Surv Ophthalmol. 2004; 49(supl. 2): S79-83.
8. Katz HR, Masket S, Lane SS et al. Absorption of topical moxifloxacin opthtalmic solution into human aqueous humor. Cornea. 2005; 24: 955-8.
9. Kim DH, Stark WJ, O’Brien TP et al. Aqueous penetration and biological activity of moxifloxacin 0,5% ophthalmic solution and gatifloxacin solution in cataract surgery patients. Ophthalmology. 2005; 112: 1992-6.
10. Kim SJ, Toma HS. Ophthalmic antibiotics and antimicrobial resistance: A randomized, controlled study of patients undergoing intravitreal injections. Ophthalmol. 2011; 118: 1358-63.
11. Lai WW, Chu KO, Chan KP et al. Differential aqueous and vitreous concentrations of moxifloxacin and ofloxacin after topical administration one hour before vitrectomy. Am J Ophthalmol. 2007; 144: 315-8.
12. Ong-Tone L. Aqueous humor penetration of gatofloxacin and moxafloxacin eyedrops given be different methods before cataract surgery. J Cataract Refract Surg. 2007; 33: 59-62.
13. McCulley JP, Caudle D, Aronowicz JD et al. Fourth-generation fluoroquinolone penetration into the aqueous humor in humans. Ophthalmology. 2006; 113: 955-9.
14. Petricek I, Prost M, Popova A. The differential diagnosis of red eye: A survey of medical practitioners from Eastern Europe and the Middle East. Ophthalmologica. 2006; 220: 229-37.
15. Prost M, Semczuk K. Antybiotykooporność szczepów bakteryjnych worka spojówkowego u dzieci. Klin Oczna. 2005; 107: 418-20.
16. Stewart WC, Crean CS, Zink RC et al. Pharmacokinetics of azithromycin and moxifloxacin in human conjunctiva and aqueous humor during and after the approved dosing regimens. Am J Ophthalmol. 2010; 150: 744-51.
17. Ta CN, Chang RT, Singh K et al. Antibiotic resistance patterns of ocular bacterial flora. Ophthalmology. 2003; 110: 1946-51.
18. Wagner RS, Abelson MB, Shapiro A et al. Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levofloxacin concentration in human conjunctival tissue. Arch Ophthalmol. 2005; 123: 182-3.
19. Yagci R, Oflu Y, Dincel A et al. Penetration of second-, third-, and fourth-generation of topical fluoroquinolone into aqueous and vitreous humour in a rabbit endophthalmitis model. Eye. 2007; 21: 990-4.
20. Yamada M, Mochizuki H, Yamada K et al. Aqueous humor levels of topically applied levofloxacin, norfloxacin and lomefloxacin in the same human eyes. J Cataract Refract Surg. 2003; 29: 1771-5.